With Integration of Biovail Nearly Completed, Valeant Looks For More Deals In 2011
This article was originally published in The Pink Sheet Daily
Executive Summary
Valeant's price-conscious, opportunistic approach to business development and relentless pace of activity has enabled it to quadruple sales in three years and grow its top-line 7% in 2010.
You may also be interested in...
The Quintessential Specialty Pharma, Valeant Embodies PE Tenets
Even as private equity firms reach into specialty pharma niche opportunities for deals, specialty pharma companies are evolving, as well. Valeant Pharmaceuticals is a very visible example of one kind of specialty pharma model, which is based as much upon sophisticated financial engineering as product growth.
Back In Biotech, Waksal's Kadmon Emerges From Stealth Mode To Focus on Hep C
Deal with Valeant brings development and commercialization rights to ribavirin analog that could have better safety profile for anemia.
Tax Benefits Highlight Announced Merger Of Valeant And Biovail
A deal that would combine two smaller specialty pharmas into one will result in a company with four main business areas.